|
Changing treatment patterns in patients with stage IV non-small cell lung cancer (NSCLC) from United States community-based oncology practices. |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - AmerisourceBergen |
Consulting or Advisory Role - AstraZeneca |
Research Funding - AstraZeneca |
|
|
|
Consulting or Advisory Role - AstraZeneca |
|
|
|
Research Funding - Xcenda |
|
|
|
|
|
|
Stock and Other Ownership Interests - AmerisourceBergen; AmerisourceBergen |
Consulting or Advisory Role - Abbvie (Inst) |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
Stock and Other Ownership Interests - GlaxoSmithKline (I) |
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech; Innate Pharma |
Research Funding - Genentech |
Travel, Accommodations, Expenses - Mirati Therapeutics |